(4-Benzhydrylmorpholin-2-yl)methanamine | 201035-03-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-Benzhydrylmorpholin-2-yl)methanamine
• CAS: 201035-03-2
• 化学式: C₁₈H₂₂N₂O
• 分子量: 282.385
• InChiKey: CXPBQHQMQFYHBW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  38.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-氨基-5-氯-2-甲氧基苯甲酸 、 (4-Benzhydrylmorpholin-2-yl)methanamine 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 4-amino-N-[(4-benzhydrylmorpholin-2-yl)methyl]-5-chloro-2-methoxybenzamide
  参考文献：
  名称：

  Novel benzamides as selective and potent gastrokinetic agents. 2. Synthesis and structure-activity relationships of 4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2-morpholinyl]methyl]benzamide citrate (AS-4370) and related compounds

  摘要：

  The title compounds (19-55) with a 4-substituted 2-(aminomethyl) morpholine group were prepared and evaluated for the gastrokinetic activity by determining their effect on gastric emptying of phenol red semisolid meal in rats. Introduction of chloro, fluoro, and trifluoromethyl groups to the benzyl group of the parent compounds 1a and 1b enhanced the activity. Among compounds tested, 4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2-morpholinyl]?? methyl]benzamide (23b) showed the most potent gastic emptying activity (effects on phenol red semisolid meal in rats and mice, and on resin pellets solid meal in rats). The gastrokinetic activity of 23b citrate (AS-4370) compared very favorably with that of cisapride and was higher than that of metoclopramide. In contrast to metoclopramide and cisapride, AS-4370 was free from dopamine D2 receptor antagonistic activity in both in vitro ([H-3]spiperone binding) and in vivo (apomorphine-induced emesis in dogs) tests.

  DOI：

  10.1021/jm00106a023
• 作为产物：
  描述：

  2-(N-acetylaminomethyl)-4-benzylmorpholine 在 palladium on activated charcoal 盐酸 、 氢气 、 potassium carbonate 、 溶剂黄146 、 potassium iodide 作用下， 以 乙醇 、 丁酮 为溶剂， 反应 21.0h， 生成 (4-Benzhydrylmorpholin-2-yl)methanamine
  参考文献：
  名称：

  Novel benzamides as selective and potent gastrokinetic agents. 2. Synthesis and structure-activity relationships of 4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2-morpholinyl]methyl]benzamide citrate (AS-4370) and related compounds

  摘要：

  The title compounds (19-55) with a 4-substituted 2-(aminomethyl) morpholine group were prepared and evaluated for the gastrokinetic activity by determining their effect on gastric emptying of phenol red semisolid meal in rats. Introduction of chloro, fluoro, and trifluoromethyl groups to the benzyl group of the parent compounds 1a and 1b enhanced the activity. Among compounds tested, 4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2-morpholinyl]?? methyl]benzamide (23b) showed the most potent gastic emptying activity (effects on phenol red semisolid meal in rats and mice, and on resin pellets solid meal in rats). The gastrokinetic activity of 23b citrate (AS-4370) compared very favorably with that of cisapride and was higher than that of metoclopramide. In contrast to metoclopramide and cisapride, AS-4370 was free from dopamine D2 receptor antagonistic activity in both in vitro ([H-3]spiperone binding) and in vivo (apomorphine-induced emesis in dogs) tests.

  DOI：

  10.1021/jm00106a023

文献信息

• Pyridyl alkene- and pyridyl alkine- acid amides as cytostatics and immuno-suppressives
  申请人：Klinge Pharma GmbH

  公开号：US20040009967A1

  公开（公告）日：2004-01-15

  The invention relates to new pyridyl alkane acid amides according to general formula (I) as well as methods for their production, medicaments containing these compounds as well as their medical use, especially in the treatment of tumors or for immunosuppression.

  本发明涉及新的吡啶基烷基酸酰胺，其通式为（I），以及其制备方法，含有这些化合物的药物以及它们在医学上的使用，特别是用于肿瘤治疗或免疫抑制。
• Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
  申请人：Klinge Pharma GmbH

  公开号：US20040029861A1

  公开（公告）日：2004-02-12

  The invention relates to the use of pharmacologically valuable pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides according to general formula (I) in the treatment of tumors or for immunosuppression. 1

  该发明涉及在肿瘤治疗或免疫抑制中使用具有药理学价值的吡啶基烷基、吡啶基烯烃和/或吡啶基炔烃酸酰胺，其通用式为（I）。1
• Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives
  申请人：Biedermann Elfi

  公开号：US20070219197A1

  公开（公告）日：2007-09-20

  The present invention relates to new pyridine compounds, methods for their production, medicaments containing these compounds as well as their use, especially in the treatment of tumor conditions and/or as cytostatic agents or as immunosuppressive agents.

  本发明涉及新的吡啶化合物，其生产方法，含有这些化合物的药物以及它们的用途，特别是在肿瘤病情的治疗中和/或作为细胞毒剂或免疫抑制剂的用途。
• Pyridyl Alkene and Pyridyl Alkine-Acid Amides as Cytostatics and Immunosuppressives
  申请人：Biedermann Elfi

  公开号：US20070142377A1

  公开（公告）日：2007-06-21

  The invention relates to a new pyridyl alkene and pyridyl alkine acid amides according to the general formula (I) as well as methods for their production, medicaments containing these compounds as well as their medical use, especially in the treatment of tumors or for immunosuppression.

  该发明涉及一种新的吡啶基烯和吡啶基炔酸酰胺，其符合通式（I），以及其制备方法，含有这些化合物的药物以及它们在医学上的应用，特别是在肿瘤治疗或免疫抑制方面的应用。
• PYRIDYL ALKENE- AND PYRIDYL ALKINE- ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES
  申请人：Fujisawa Deutschland GmbH

  公开号：EP0923570B1

  公开（公告）日：2002-09-25